Overview
Malignant neoplasms of the brain encompass a diverse group of aggressive tumors that originate within the central nervous system (CNS) or metastasize to it from distant primary sites. These malignancies pose significant clinical challenges due to their rapid growth, infiltrative nature, and profound impact on neurological function. The most common primary brain malignancies include glioblastoma multiforme (GBM), astrocytomas, oligodendrogliomas, and medulloblastomas, while metastatic brain tumors frequently originate from lung, breast, melanoma, and renal cancers. The epidemiology of brain malignancies reveals complex trends influenced by demographic factors, with notable variations in mortality rates across racial groups and age cohorts. Advances in imaging techniques and data preprocessing methodologies, such as SUSAN denoising and ComBat harmonization, have significantly enhanced diagnostic accuracy and prognostic modeling, thereby improving patient outcomes and treatment planning.
Epidemiology
Between 1999 and 2020, the epidemiology of malignant brain neoplasms has shown a nuanced pattern in mortality trends. Initially, both crude and age-adjusted mortality rates (AAMRs) per 100,000 individuals experienced a significant decline, with an average percent change (APC) of -1.4 until around 2006, likely attributed to improvements in diagnostic techniques and therapeutic interventions. However, this trend reversed post-2006, with a gradual increase in AAMRs reaching an APC of 0.4 by 2020, suggesting potential challenges in treatment efficacy or changes in risk factors [PMID:41143922]. Demographic disparities in mortality rates are also evident, with non-Hispanic Whites exhibiting the highest AAMR at 7.5 per 100,000 individuals, compared to non-Hispanic Asians or Pacific Islanders, who have the lowest rate at 3.0 per 100,000 [PMID:41143922]. These variations highlight the importance of considering demographic factors in epidemiological studies and public health strategies.
The inherently susceptible subpopulation for malignant brain neoplasms, as estimated by Dolejs [PMID:9593324], comprises approximately 0.390% of men and 0.417% of women. This relatively small proportion underscores the need for targeted screening and risk assessment strategies, particularly in identifying those at higher risk earlier in life. The observed decline in mortality rates with increasing age, as noted by Dolejs, suggests that while incidence might increase with age, advancements in healthcare and treatment efficacy may mitigate mortality in older populations. Understanding these patterns is crucial for forecasting future trends and allocating resources effectively in healthcare systems.
Diagnosis
Accurate diagnosis of malignant brain neoplasms is pivotal for guiding appropriate treatment and improving patient outcomes. Imaging modalities, particularly magnetic resonance imaging (MRI), remain the cornerstone of initial diagnosis. Advanced image processing techniques, such as SUSAN denoising, have significantly enhanced the diagnostic accuracy by reducing noise and enhancing contrast between tumor types and normal brain tissue [PMID:38604733]. This method has been particularly effective in distinguishing between glioblastoma, intracranial metastatic disease, and primary central nervous system (CNS) lymphoma, which can present with overlapping imaging features but require distinct therapeutic approaches.
Differential diagnosis often hinges on clinical presentation, imaging characteristics, and sometimes cerebrospinal fluid (CSF) analysis or biopsy results. For instance, glioblastoma typically appears as a heterogeneous mass with necrosis and peritumoral edema on MRI, while metastatic lesions often demonstrate characteristic patterns based on their primary origin. Primary CNS lymphomas may show more homogeneous enhancement patterns without significant surrounding edema. The integration of machine learning algorithms with preprocessed MRI data using techniques like SUSAN denoising and ComBat harmonization further refines diagnostic precision, aiding clinicians in tailoring management strategies more accurately [PMID:38604733]. Regular follow-up imaging is essential to monitor disease progression or recurrence, typically scheduled every 3-6 months initially, adjusting based on clinical response and patient stability.
Management
The management of malignant brain neoplasms involves a multidisciplinary approach, encompassing surgical resection, radiation therapy, chemotherapy, and supportive care tailored to the specific type and stage of the tumor. For glioblastoma multiforme (GBM), the standard frontline treatment includes maximal safe surgical resection followed by adjuvant temozolomide chemotherapy and radiotherapy [Stupp protocol]. The dose of temozolomide is typically 75 mg/m2 daily for 7 days, concurrent with radiotherapy (54 Gy in 30 fractions), followed by maintenance temozolomide (200 mg/m2 days 1-5 every 28 days) for 6 cycles [PMID:26773579].
Radiosurgery and stereotactic radiotherapy are increasingly utilized for both primary and metastatic lesions, especially in cases where surgical resection is not feasible or poses significant risks. Targeted therapies, such as bevacizumab for recurrent GBM, have shown promise in extending progression-free survival by inhibiting angiogenesis [PMID:21742469]. Regular monitoring through MRI scans is crucial, with intervals typically every 3-6 months initially, then adjusted based on clinical response and disease stability.
Advanced preprocessing techniques, such as SUSAN denoising and ComBat harmonization applied to MRI data, not only enhance diagnostic accuracy but also improve the precision of treatment planning. These methods reduce variability in imaging data, leading to more reliable models for predicting treatment response and disease progression. Clinicians should leverage these technological advancements to refine patient-specific treatment protocols, ensuring that interventions are optimized for efficacy and minimized toxicity.
Prognosis & Follow-up
The prognosis for patients with malignant brain neoplasms varies widely depending on the specific type of tumor, extent of disease, and response to treatment. Glioblastoma multiforme (GBM) generally carries the poorest prognosis, with median survival rates typically around 12-18 months from diagnosis despite aggressive treatment [PMID:26773579]. Metastatic brain tumors have prognoses that correlate closely with the status and control of the primary malignancy, with survival often measured in months if multiple metastases are present. Primary CNS lymphomas, particularly those in immunocompetent individuals, can achieve better outcomes with chemotherapy, sometimes extending survival beyond two years [PMID:29724677].
Advanced preprocessing techniques in MRI data, such as SUSAN denoising and ComBat harmonization, contribute significantly to more reliable prognostic indicators by minimizing variability and enhancing the accuracy of imaging-based assessments. These methods allow for better stratification of patients into prognostic subgroups, facilitating personalized treatment plans and more accurate predictions of disease progression. Regular follow-up is essential, typically involving MRI scans every 3-6 months initially, with adjustments based on clinical status and treatment response. Clinically, monitoring includes assessing neurological function, cognitive status, and quality of life, alongside imaging findings.
End-of-life care considerations are also critical, given that nearly half (48.9%) of deaths due to primary malignant brain neoplasms (PMBN) occur at home, highlighting potential gaps in access to palliative care services or end-of-life support [PMID:41143922]. Ensuring comprehensive palliative care integration can significantly improve symptom management and patient comfort, addressing both physical and psychological needs. Recognizing the limited size of the susceptible population (0.390% for men, 0.417% for women) as noted by Dolejs [PMID:9593324] can aid in targeted surveillance and early intervention strategies, potentially mitigating some of the prognostic challenges faced by these patients.
Key Recommendations
References
1 Bathla G, Soni N, Mark IT, Liu Y, Larson NB, Kassmeyer BA et al.. Impact of SUSAN Denoising and ComBat Harmonization on Machine Learning Model Performance for Malignant Brain Neoplasms. AJNR. American journal of neuroradiology 2024. link 2 Khan SMI, Waqas M, Ahmed SZ, Qadeer MA, Ashraf H, Ashfaq H et al.. Trends in primary malignant brain neoplasms associated mortality among individuals of age 25 years and older in united States from 1999 to 2020: a gender, race and demographics based analysis of CDC wonder database. Neurosurgical review 2025. link 3 Dolejs J. The size of the subpopulation susceptible to malignant neoplasm of the brain. Mechanisms of ageing and development 1998. link00180-2)